DEFT misses Nasdaq $1 cure deadline, enters listing review
The reverse split is authorized but unused, leaving the board's hand forced if Nasdaq grants a second cure window: the only remaining lever to clear the $1 bid rule is exactly what shareholders…
CryptoSlate